Carmela Mocerino

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna et al. · The Breast · 2019 · 57 citations

Medicine, Oncology, Breast Oncology +9

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study

Francesca Carlino, Anna Diana, Anna Ventriglia et al. · Cancers · 2022 · 36 citations · Full text

Medicine, Endocrinology, Oncology +16

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

Antongiulio Faggiano, Silvana Di Maio, Carmela Mocerino et al. · Endocrine · 2019 · 35 citations · Full text

Medicine, Endocrinology, Oncology +12

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life

Antongiulio Faggiano, Anna Chiara Carratù, Elia Guadagno et al. · Oncotarget · 2015 · 34 citations · Full text

Medicine, Endocrinology, Oncology +17